Evidence map›Paper›PMID 37007477›Full record

ReviewFrontiers in microbiology2023

Bioengineering of fungal endophytes through the CRISPR/Cas9 system.

Vinita Verma, Arpita Batta, Harikesh B Singh, Alok Srivastava, Sanjay Kumar Garg, Vijay Pal Singh, Pankaj Kumar Arora

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vinita VermaDepartment of Environmental Microbiology, Babasaheb Bhimrao Ambedkar University, Lucknow, India.
Arpita BattaDepartment of Biotechnology, Institute of Engineering and Technology, Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India.
Harikesh B SinghDepartment of Biotechnology, GLA University, Mathura, Uttar Pradesh, India.
Alok SrivastavaDepartment of Plant Science, Faculty of Applied Sciences, MJP Rohilkhand University, Bareilly, India.
Sanjay Kumar GargDepartment of Plant Science, Faculty of Applied Sciences, MJP Rohilkhand University, Bareilly, India.
Vijay Pal SinghDepartment of Plant Science, Faculty of Applied Sciences, MJP Rohilkhand University, Bareilly, India.
Pankaj Kumar AroraDepartment of Environmental Microbiology, Babasaheb Bhimrao Ambedkar University, Lucknow, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CRISPR/Cas9 system is a genome-editing tool that allows for precise and efficient modifications to the DNA of a cell. This technology can be used in endophytic fungi, which live within plants and can have beneficial effects on their host, making them important for agriculture. Using CRISPR/Cas9, researchers can introduce specific genetic changes into endophytic fungal genomes, allowing them to study the function of genes, improve their plant-growth-promoting properties, and create new, more beneficial endophytes. This system works by using the Cas9 protein, which acts as a pair of molecular scissors, to cut DNA at specific locations determined by a guide RNA. Once the DNA is cut, the cell's natural repair mechanisms can be used to insert or delete specific genes, allowing for precise editing of the fungal genome. This article discusses the mechanism and applications of CRISPR/Cas9 to fungal endophytes.

Indexed as

bioactive compoundsbioengineeringCRISPR/Cas9 technologyfungal endophytesmetabolite

Identifiers

PMID37007477
PMCPMC10060627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.